e.g. mhealth
Search Results (1 to 10 of 11 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 3 Journal of Medical Internet Research
- 2 JMIR Cancer
- 2 JMIR Research Protocols
- 1 JMIR Bioinformatics and Biotechnology
- 1 JMIR Medical Informatics
- 1 JMIR Public Health and Surveillance
- 1 JMIRx Med
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Medical Education
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 JMIR Formative Research
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Contemporary treatment strategies have led to improved life expectancy after treatment for pediatric cancer, especially in survivors of acute lymphocytic leukemia (ALL) [3]. Given that studies have shown that the promotion of a healthy lifestyle and interventions that reduce physical and mental health burdens can lead to reduction in all-cause and cause-specific mortality, addressing the risk factors of adverse functional outcomes early on is critical [4-6].
JMIR Bioinform Biotech 2025;6:e65001
Download Citation: END BibTex RIS
These immunotherapeutic strategies have received approval for the treatment of several cancer types such as lung cancer, prostate cancer, chronic lymphocytic leukemia, and non-Hodgkin lymphoma [2]. Immunotherapy offers substantial benefits in terms of precision, specificity, and long-term survival improvements, representing a significant breakthrough in cancer treatment [3].
Immunotherapy has made remarkable progress and demonstrated clinical value.
J Med Internet Res 2025;27:e60948
Download Citation: END BibTex RIS
Inclusion criteria
Used tool: Google Trends
Health domain: solid tumor, lymphoma, leukemia, multiple myeloma, and their screening method
Language: English
Type of paper: original research, brief report, letter to the editor, etc
Exclusion criteria
Used tool: other tools related to search engines statistics than Google Trends
Health domain: not using at least one search term or topic related to malignancy or their screening method
Language: non-English
Type of paper: conference abstract
We used the Pub Med search
J Med Internet Res 2023;25:e47582
Download Citation: END BibTex RIS
In a Kenyan study, parents of children receiving treatment for leukemia reported anxiety, shock, fatigue, and economic challenges, which were associated with heightened family tension and increased need for emotional support [15].
JMIR Res Protoc 2023;12:e48799
Download Citation: END BibTex RIS
Among blood cancers, multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) are the 2nd and 3rd most common types, respectively, and are considered incurable. MM and CLL have a chronic relapsing remitting course that often requires multiple lines of treatment [6,7]. This increases the potential for disease and treatment-related physical symptoms and emotional distress [6-9].
Interventions that target physical and emotional symptoms are lacking for blood cancer survivors.
JMIR Cancer 2023;9:e44533
Download Citation: END BibTex RIS
The Patient Experience of Acute Lymphoblastic Leukemia and Its Treatment: Social Media Review
Acute lymphoblastic leukemia (ALL) is an aggressive cancer of the blood and bone marrow that rapidly progresses and affects immature blood cells rather than mature ones [1]. ALL is the most common childhood cancer (ie, in patients under 18 years of age, the median age of diagnosis is 15 years), but it also accounts for approximately 20% of adult leukemias [2,3]. Childhood ALL has a cure rate as high as 90%, but the cure rate for adults is substantially lower, ranging from 20% to 40% [1,3,4].
JMIR Cancer 2023;9:e39852
Download Citation: END BibTex RIS
Reference 53: Precision medicine in acute lymphoblastic leukemia Reference 62: Treatment outcomes of pediatric acute myeloid leukemia: a retrospective analysis from 1996 results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemialeukemiaThe Health Care Utilization and Medical Costs in Long-Term Follow-Up of Children Diagnosed With Leukemia
JMIR Public Health Surveill 2023;9:e42350
Download Citation: END BibTex RIS
Acute lymphoblastic leukemia is a malignant cancer of the white blood cells characterized by uncontrolled overproduction and accumulation of lymphoid progenitor cells [1]. It is most common among children, which compromise 80% of the worldwide acute lymphoblastic leukemia occurrences, although some cases in adults are also seen. It is equally life-threatening in both cases. In the United States, acute lymphoblastic leukemia is estimated to have a frequency of 1.7 cases per 100,000 people [2].
JMIRx Med 2021;2(3):e29844
Download Citation: END BibTex RIS
For example, careful evaluation of how long patients with leukemia can be managed without in-person follow-up visits, blood tests, and therapies, as well as close monitoring of potential complications during therapy, are now critical components of patient management during this global pandemic [8]. Therefore, special recommendations to optimize treatments for patients with hematologic malignancies during the COVID-19 pandemic have been recently published [8].
JMIR Res Protoc 2021;10(6):e25271
Download Citation: END BibTex RIS
Baseline characteristics in three study cohorts.
a ALL: acute lymphoblastic leukemia.
b AML: acute myeloid leukemia.
c MDS: myelodysplastic syndrome.
d AA: aplastic anemia.
e MM: myeloma.
f MPD: myeloproliferative disease.
To validate the model performance in real-world clinical practice, we designed a validation cohort for evaluating the disease severity of leukemia and MDS. We included 70 bone marrow smears from January 1, 2017, to June 30, 2018, with acute leukemia and MDS before and after treatment.
JMIR Med Inform 2020;8(4):e15963
Download Citation: END BibTex RIS